Author:
Wu Pei-Tzu,Huang Kun-Long,Tsai Ching-Chang,Cheng Hsin-Hsin,Lai Yun-Ju,Hsu Te-Yao
Abstract
Abstract
Background
Ritodrine hydrochloride is a widely used beta-adrenergic agonist used to stop preterm labor in Taiwan. Many side effects causing maternal morbidity and mortality have been reported. We report a case complicated with ritodrine-induced side effects and mirror syndrome that was associated with placental chorioangioma.
Case presentation
A 36-year-old singleton pregnant woman at 25 6/7 weeks of gestation, with an undiagnosed placental chorioangioma, underwent tocolysis due to preterm uterine contractions. Her clinical condition deteriorated, attributed to mirror syndrome and adverse events induced by ritodrine. An emergency cesarean section was performed at 27 1/7 weeks of gestation, delivering an infant with generalized subcutaneous edema. A placental tumor measuring 8.5 cm was discovered during the operation, and pathology confirmed chorioangioma. Gradual improvement in her symptoms and laboratory data was observed during the postpartum period. Identifying mirror syndrome and ritodrine-induced side effects poses challenges. Therefore, this case is educational and warrants discussion.
Conclusion
Our case demonstrates mirror syndrome induced by chorioangioma, which is rare, and ritodrine-induced side effects. The cessation of intravenous ritodrine and delivery are the best methods to treat maternal critical status due to fluid overload.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Gerris J, Bracke M, Thiery M, Van Maele G. Cardiotoxicity of ritodrine: assessment based on serum creatine kinase activity. Z Geburtshilfe Perinatol. 1980;184(1):25–30.
2. Pisani RJ, Rosenow EC. 3rd: pulmonary edema associated with tocolytic therapy. Ann Intern Med. 1989;110(9):714–8.
3. Minakami H, Takahashi T, Izumi A, Itoi H, Tamada T. Enlargement of the salivary gland after ritodrine treatment in pregnant women. BMJ. 1992;304(6843):1668.
4. Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the US Food and Drug Administration. Intern Med. 2011;50(8):845–53.
5. Daimon A, Nunode M, Sano T, Tanaka T, Fujita D, Ohmichi M. Ritodrine-Induced Agranulocytosis: A Case Report and Literature Review. Case Rep Obstet Gynecol 2020, 2020:5846161.